{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:08:35Z","timestamp":1790964515360,"version":"4.1.0"},"reference-count":141,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013538","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T01:52:36Z","timestamp":1583459556000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer"],"prefix":"10.1002","author":[{"given":"Kim Tam","family":"Bui","sequence":"first","affiliation":[{"name":"Concord Repatriation General Hospital; Medical Oncology Department; 1A Hospital Road Concord NSW Australia 2137"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina L","family":"Willson","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shom","family":"Goel","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre; Melbourne Australia"},{"name":"University of Melbourne; Sir Peter MacCallum Department of Oncology; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Beith","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse; Camperdown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Concord Repatriation General Hospital; Medical Oncology Department; 1A Hospital Road Concord NSW Australia 2137"},{"name":"The University of Sydney, Concord Repatriation General Hospital; Concord Clinical School; Concord NSW Australia 2137"},{"name":"Sydney Local Health District and South Western Sydney Local Health District; Cancer Genetics Department; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD013538-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djk109","article-title":"Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial","volume":"99","author":"Adjuvant Breast Cancer Trials Collaborative Group","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD013538-BIB0002|cit2","unstructured":"Anonymous Phase III randomised study of adjuvant therapy with tamoxifen vs endocrine ablation vs tamoxifen plus endocrine ablation vs neoadjuvant therapy in patients under 50 with operable breast cancer UKCCCR National Register of Cancer Trials 1997"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD013538-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/jco.2004.22.90140.8015","article-title":"The impact on quality of life of adding chemotherapy (CT) or ovarian suppression (OS) to adjuvant tamoxifen (TAM): outcomes from the UK NCRI Adjuvant Breast Cancer (ABC) trial","volume":"22","author":"Brunt","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013538-BIB0004|cit4","first-page":"S1","article-title":"Results from the UK NCRI adjuvant breast cancer (ABC) international trial: polychemotherapy and ovarian ablation in women with early breast cancer prescribed 5 years tamoxifen","volume":"91","author":"Brunt","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0005|cit5","unstructured":"George WD Phase III randomised study of adjuvant tamoxifen with or without ovarian suppression and\/or cyclophosphamide\/methotrexate\/fluorouracil (CMF) in premenopausal women with operable invasive breast cancer Physician Data Query (PDQ) 1994"},{"key":"10.1002\/14651858.CD013538-BIB0006|cit6","unstructured":"NCT00002582 Tamoxifen, ovarian ablation, and\/or chemotherapy in treating women with stage 1, stage II or stage IIIA breast cancer clinicaltrials.gov\/show\/NCT00002582,"},{"key":"10.1002\/14651858.CD013538-BIB0008|cit7","unstructured":"Yarnold JR Phase III randomised study of adjuvant tamoxifen, ovarian suppression, and\/or chemotherapy in women with T1-3a, N0-1, M0 breast cancer Physician Data Query (PDQ) 1995"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD013538-BIB0007|cit8","first-page":"Abstract no. 53","article-title":"Ovarian ablation (OA) in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T plus chemotherapy (CT) - results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients","volume":"22","author":"Yarnold","year":"2004","journal-title":"American Society of Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0011|cit9","unstructured":"Arriagada R Phase III randomised study of ovarian suppression in premenopausal women receiving adjuvant chemotherapy for poor-prognosis nonmetastatic breast cancer Physician Data Query (PDQ) 1995"},{"key":"10.1002\/14651858.CD013538-BIB0010|cit10","first-page":"no.4","article-title":"Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"22","author":"Arriagada","year":"2003","journal-title":"American Society of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013538-BIB0009|cit11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/annonc\/mdi085","article-title":"Randomized trial of adjuvant ovarian suppression in 926 pre-menopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"16","author":"Arriagada","year":"2005","journal-title":"Annals of Oncology"},{"issue":"319","key":"10.1002\/14651858.CD013538-BIB0012|cit12","first-page":"1","article-title":"The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0013|cit13","first-page":"1","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"37","author":"Kim","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0014|cit14","first-page":"Abstract no. P4","article-title":"Time course of changes in serum FSH, serum estradiol, and menstruation in premenopausal patients with breast cancer taking tamoxifen after completing chemotherapy: a report from the ASTRRA study","volume":"79","author":"Kim","year":"2018","journal-title":"San Antonio Bresat Cancer Symposium"},{"key":"10.1002\/14651858.CD013538-BIB0015|cit15","unstructured":"NCT00912548 Evaluating the role of the addition of ovarian function suppression (OFS) to tamoxifen in young women (ASTRRA) clinicaltrials.gov\/show\/NCT00912548,"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013538-BIB0016|cit16","first-page":"Abstract no. 50","article-title":"Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study","volume":"36","author":"Noh","year":"2018","journal-title":"American Society of Oncology (ASCO)"},{"key":"10.1002\/14651858.CD013538-BIB0017|cit17","first-page":"5a","article-title":"Phase III comparison of tamoxifen versus tamoxifen and ovarian ablation in premenopausal women with axillary node-negative receptor=positive breast cancer < 3cm","volume":"22","author":"Robert","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"35","key":"10.1002\/14651858.CD013538-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0019|cit19","unstructured":"Davidson N O\u2019Neil A Vukov A Effect of chemohormonal therapy in pre-menopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101) Proceedings of the American Society of Clinical Oncology 2003 Abstract 15"},{"issue":"25","key":"10.1002\/14651858.CD013538-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1200\/JCO.2005.05.551","article-title":"Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)","volume":"23","author":"Davidson","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD013538-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ejca.2007.08.012","article-title":"A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93","volume":"43","author":"Kaufmann","year":"2007","journal-title":"European Journal of Cancer"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD013538-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/jco.2004.22.90140.588","article-title":"Goserelin versus control after adjuvant, risk adapted chemotherapy in premenopausal women with breast cancer. GABG trial IV-B-93","volume":"22","author":"Kaufmann","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013538-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/oxfordjournals.annonc.a058976","article-title":"The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up","volume":"5","author":"Castiglione-Gertsch","year":"1994","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013538-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oxfordjournals.annonc.a057670","article-title":"Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients","volume":"1","author":"International Breast Cancer Study Group","year":"1990","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013538-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.1985.3.8.1059","article-title":"Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer","volume":"3","author":"Ludwig Breast Cancer Study Group","year":"1985","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013538-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2005.04.5393","article-title":"Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients - the International Breast Cancer Study Group Trial VIII","volume":"25","author":"Bernhard","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0027|cit27","unstructured":"Castiglione-Gertsch M O\u2019Neill A Gelber RD Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre\/perimenopausal breast cancer patients (pts) who receive goserelin? First results of IBCSG trial VIII Proceedings of the American Society of Clinical Oncology 2001 Abstract 149"},{"issue":"24","key":"10.1002\/14651858.CD013538-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial","volume":"95","author":"International Breast Cancer Study Group","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"10","key":"10.1002\/14651858.CD013538-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1093\/annonc\/mdq735","article-title":"Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer","volume":"22","author":"Karlsson","year":"2011","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0030|cit30","first-page":"Abstract no. 58","article-title":"Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy","volume":"32","author":"Bellet","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD013538-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen for the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0032|cit32","first-page":"Abstract no. 55","article-title":"Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC)","volume":"32","author":"Bernhard","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013538-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013538-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4161\/15384047.2014.972783","article-title":"Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer","volume":"15","author":"Figg","year":"2014","journal-title":"Cancer Biology & Therapy"},{"key":"10.1002\/14651858.CD013538-BIB0035|cit35","unstructured":"Fleming G Francis P Phase III randomized study of ovarian function suppression in combination with tamoxifen versus ovarian function suppression in combination with exemestane versus tamoxifen alone in premenopausal women with endocrine-responsive breast cancer Physician Data Query (PDQ) 2003"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0036|cit36","first-page":"GS4","article-title":"Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the SOFT trial","volume":"78","author":"Fleming","year":"2017","journal-title":"Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0037|cit37","first-page":"OT3","article-title":"Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer","volume":"77","author":"Francis","year":"2017","journal-title":"Cancer Research. Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013538-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0040|cit40","first-page":"14","article-title":"Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): analysis of the SOFT trial","volume":"75","author":"Goldhirsch","year":"2015","journal-title":"Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium"},{"issue":"1","key":"10.1002\/14651858.CD013538-BIB0041|cit41","first-page":"5","article-title":"SOFT trial endorses selective ovarian suppression in early breast cancer","volume":"11","author":"Jancin","year":"2015","journal-title":"Oncology Report"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0042|cit42","first-page":"14","article-title":"CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer","volume":"75","author":"Johansson","year":"2015","journal-title":"Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium"},{"issue":"1","key":"10.1002\/14651858.CD013538-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13058-016-0771-8","article-title":"Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial","volume":"18","author":"Johansson","year":"2016","journal-title":"Breast Cancer Research"},{"key":"10.1002\/14651858.CD013538-BIB0044|cit44","unstructured":"NCT00066690 Suppression of ovarian function with either tamoxifen or exemestane compared with tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer (SOFT) clinicaltrials.gov\/ct2\/show\/NCT00066690"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0045|cit45","first-page":"GS4","article-title":"Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials","volume":"78","author":"Pagani","year":"2018","journal-title":"Cancer Research. Conference: San Antonio Breast Cancer Symposium, SABCS 2017"},{"key":"10.1002\/14651858.CD013538-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.breast.2016.02.008","article-title":"Are SOFT and TEXT results practice changing and how?","volume":"27","author":"Pagani","year":"2016","journal-title":"The Breast"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0047|cit47","first-page":"GS4","article-title":"Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials","volume":"32","author":"Pagani","year":"2014","journal-title":"Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0049|cit49","first-page":"P1","article-title":"Co-SOFT: the cognitive function substudy of the suppression of ovarian function trial (SOFT)","volume":"75","author":"Phillips","year":"2015","journal-title":"Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium"},{"issue":"9","key":"10.1002\/14651858.CD013538-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/bjc.2016.71","article-title":"Adjuvant ovarian function suppression and cognitive function in women with breast cancer","volume":"114","author":"Phillips","year":"2016","journal-title":"British Journal of Cancer"},{"issue":"19","key":"10.1002\/14651858.CD013538-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013538-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.breast.2013.08.009","article-title":"Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials","volume":"22","author":"Regan","year":"2013","journal-title":"Breast"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-015-3612-z","article-title":"Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials","volume":"154","author":"Regan","year":"2015","journal-title":"Breast Cancer Treatment and Treatment"},{"issue":"9","key":"10.1002\/14651858.CD013538-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/annonc\/mdx285","article-title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT","volume":"28","author":"Regan","year":"2017","journal-title":"Annals of Oncology"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0055|cit55","first-page":"14","article-title":"Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po","volume":"75","author":"Ribi","year":"2015","journal-title":"Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium"},{"issue":"14","key":"10.1002\/14651858.CD013538-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial","volume":"34","author":"Ribi","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD013538-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","article-title":"Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials","volume":"35","author":"Saha","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"24 Suppl 3","key":"10.1002\/14651858.CD013538-BIB0058|cit58","first-page":"OT2","article-title":"SOFT and TEXT: Trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor-positive early breast cancer","volume":"72","author":"Zickl","year":"2012","journal-title":"Cancer Research. Conference: 35th Annual CTRC AACR San Antonio Breast Cancer Symposium"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0059|cit59","first-page":"161","article-title":"Adjuvant combination chemotherapy (CMFVP) versus oophorectomy followed by CMFVP (OCMFVP) for premenopausal women with ER+ operable breast cancer with positive axillary lymph nodes: an intergroup study","volume":"19","author":"Rivkin","year":"1991","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD013538-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.1996.14.1.46","article-title":"Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study","volume":"14","author":"Rivkin","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013538-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4103\/0019-509X.175301","article-title":"The outcome effect of double-hormonal therapy in premenopausal breast cancer patients with high nodal-status: result of a prospective randomized trial","volume":"51","author":"Uslu","year":"2014","journal-title":"Indian Journal of Cancer"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013538-BIB0062|cit62","first-page":"Abstract no. 56","article-title":"Goserelin plus tamoxifen versus tamoxifen alone in pre-or peri-menopausal patients with hormone receptor-positive early-stage breast cancer: a randomized, controlled clinical trial in China","volume":"34","author":"Yang","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013538-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/bjc.2013.324","article-title":"Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial","volume":"109","author":"Yang","year":"2013","journal-title":"British Journal of Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013538-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.ejca.2016.03.032","article-title":"Goserelin plus tamoxifen versus tamoxifen alone, in pre-menopausal or peri-menopausal patients with hormone receptor-positive early stage breast cancer: a randomised controlled trial in China","volume":"60","author":"Yang","year":"2016","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013538-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4306\/pi.2017.14.4.491","article-title":"Agoraphobia and follicle-stimulating hormone levels between tamoxifen and goserelin versus tamoxifen alone in premenopausal hormone receptor-positive breast cancer: a 12-month prospective randomized study","volume":"14","author":"Heo","year":"2017","journal-title":"Psychiatry Investigation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013538-BIB0067|cit66","first-page":"S138","article-title":"Comparisons of anxiety and depression between premenopausal women who received tamoxifen and goserelin versus tamoxifen alone to manage breast cancer: a 12-month prospective randomized study","volume":"57","author":"Yi","year":"2016","journal-title":"European Journal of Cancer"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013538-BIB0066|cit67","first-page":"Abstract no. P1","article-title":"Depression and anxiety after adjuvant ovarian function suppression in premenopausal breast cancer patients","volume":"76","author":"Yi","year":"2016","journal-title":"Cancer Research"},{"issue":"13","key":"10.1002\/14651858.CD013538-BIB0068|cit68","first-page":"2071","article-title":"Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan - Zoladex Breast Cancer Study Group Trial-B [Japanese]","volume":"32","author":"Mitsuyama","year":"2005","journal-title":"Japanese Journal of Cancer Chemotherapy [Gan To Kagaku Ryoho]"},{"issue":"7","key":"10.1002\/14651858.CD013538-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2005.12.013","article-title":"Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study","volume":"42","author":"Baum","year":"2006","journal-title":"European Journal of Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013538-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000181353","article-title":"Cancer Research Campaign Adjuvant Breast Trial for patients under 50","volume":"32","author":"Baum","year":"1989","journal-title":"Hormone Research"},{"key":"10.1002\/14651858.CD013538-BIB0071|cit71","unstructured":"Baum M Houghton J Sawyer W Management of pre-menopausal women with early breast cancer: is there a role for goserelin? Proceedings of the American Society of Clinical Oncology 2001 Abstract no. 103"},{"issue":"5","key":"10.1002\/14651858.CD013538-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/djn498","article-title":"Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer","volume":"101","author":"Hackshaw","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD013538-BIB0073|cit73","first-page":"Abstract no. 34","article-title":"Expression of c-erbB-2 is correlated with expression of vascular endothelial growth factor receptor 2 (VEGFR2\/KDR), VEGF and VERFR1 in premenopausal patients with primary human breast cancer receiving adjuvant endocrine therapy within a randomized phase III trial (ZIPP trial)","volume":"861","author":"Linderholm","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0074|cit74","unstructured":"NCT00002460 Adjuvant hormone therapy in treating women with operable breast cancer clinicaltrials.gov\/ct2\/show\/NCT00002460"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013538-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0959-8049(99)80702-3","article-title":"Adjuvant treatment of premenopausal breast cancer with zoladex and tamoxifen: results from randomised trials by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, The Stockholm Breast Cancer Study Group, the South East Sweden Breast Cancer Group and Gruppo Interdisciplinare Valutazione Intervention Oncologia (GIVIO)","volume":"35","author":"Nordenskjold","year":"1999","journal-title":"European Journal of Cancer Supplement"},{"key":"10.1002\/14651858.CD013538-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.2003.04.024","article-title":"Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomised study","volume":"21","author":"Nystedt","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013538-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10549-011-1593-0","article-title":"Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer","volume":"128","author":"Sverrisdottir","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD013538-BIB0078|cit78","first-page":"S1","article-title":"Abstract S1-5: interaction between goserelin and tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer","volume":"70","author":"Sverrisdottir","year":"2010","journal-title":"Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD013538-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10549-009-0313-5","article-title":"Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial","volume":"117","author":"Sverrisdottir","year":"2009","journal-title":"Breast Cancer Research and Treatment"},{"issue":"7","key":"10.1002\/14651858.CD013538-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013538-BIB0081|cit81","first-page":"10-1 (abstract","article-title":"The impact of treatment-induced amenorrhea on survival of premenopausal patients with endocrine-responsive breast cancer: 10-year results of ABCSG-05 (CMF vs. goserelin+tamoxifen)","volume":"100 Suppl 1","author":"Gnant","year":"2006","journal-title":"Breast Cancer Research and Treatment"},{"issue":"24","key":"10.1002\/14651858.CD013538-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2002.09.112","article-title":"Randomised adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in pre-menopausal patients with hormone responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group trial 5","volume":"20","author":"Jakesz","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0083|cit83","unstructured":"Baum M Phase III randomised study of adjuvant therapy with camomile vs endocrine ablation vs camomile plus endocrine ablation vs no adjuvant therapy in patients under age 50 with operable breast cancer PDQ 1996"},{"issue":"8","key":"10.1002\/14651858.CD013538-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdl107","article-title":"Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node- positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial","volume":"17","author":"Roche","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0085|cit85","unstructured":"Roche H Kerbrat P Bonneterre J Complete hormonal blockade versus chemotherapy in pre-menopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: results of the FASG 06 trial Proceedings of the American Society of Clinical Oncology 2000 72a (abstract 279)"},{"key":"10.1002\/14651858.CD013538-BIB0086|cit86","doi-asserted-by":"crossref","unstructured":"von Minckwitz G Graf E Geberth M Eiermann W Jonat W Conrad B Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal women. The GABG trial IV-A-93 Trial Proceedings of the American Society of Clinical Oncology 2004 11s (abstract 534)","DOI":"10.1200\/jco.2004.22.90140.534"},{"key":"10.1002\/14651858.CD013538-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.ejca.2006.04.006","article-title":"CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)","volume":"42","author":"Minckwitz","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0088|cit88","unstructured":"von Minckwitz G von de Assesn A Conrad B Medical ovarian ablation versus polychemotherapy in premenopausal women with node-negative, receptor positive breast cancer. The ongoing trial 'A-93' of the German Adjuvant Greast Cancer Group (GABG) Proceedings of the American Society of Clinical Oncology 1999 (abstract 395)"},{"issue":"14","key":"10.1002\/14651858.CD013538-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2000.18.14.2718","article-title":"Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of oestrogen receptor-positive pre-\/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomised trial","volume":"18","author":"Boccardo","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0090|cit90","unstructured":"Boccardo F Rubagotti A Amoroso D CMF versus tamoxifen (TAM) plus goserelin (GOS) as adjuvant treatment of ER positive (ER+) pre-perimenopausal breast cancer (CA) patients (PTS). Preliminary results of the GROCTA 02 study Proceedings of the American Sociey of Clinical Oncology 1998 abstract 382"},{"key":"10.1002\/14651858.CD013538-BIB0091|cit91","first-page":"101","article-title":"CMF versus tamoxifen plus goserelin as adjuvant treatment of ER-positive pre-perimenopausal breast cancer patients: preliminary results of an ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) trial","volume-title":"Adjuvant Therapy of Cancer VIII","author":"Boccardo","year":"1997"},{"key":"10.1002\/14651858.CD013538-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2016.03.001","article-title":"Epirubicin dose and sequential hormonal therapy - Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer","volume":"60","author":"Coombes","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CMAR.S183672","article-title":"Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Management and Research"},{"key":"10.1002\/14651858.CD013538-BIB0094|cit94","unstructured":"Bianco AR Costanzo R Di Lorenzo G The MAM-1 GOCSI trial: a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node positive (N+) early breast cancer (ebc) Proceedings of the American Society of Clinical Oncology 2001 27a (abstract 104)"},{"issue":"3","key":"10.1002\/14651858.CD013538-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bjc.6602355","article-title":"A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer","volume":"92","author":"Placido","year":"2005","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/M19-0274","article-title":"Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial","volume":"171","author":"Manson","year":"2019","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013538-BIB0097|cit97","unstructured":"Premenopausal endocrine responsive chemotherapy trial (PERCHE) clinicaltrials.gov\/show\/NCT00066807"},{"key":"10.1002\/14651858.CD013538-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Falkson CI Falkson HC Falkson G The effect of chemotherapy with or without GnHRA on serum hormone levels in premenopausal women with breast cancer Proceedings of the American Society of Clinical Oncology 1990 (abstract 90)","DOI":"10.1016\/0277-5379(91)90082-O"},{"issue":"Pt 2","key":"10.1002\/14651858.CD013538-BIB0099|cit99","first-page":"Abstract no.177","article-title":"Cyclophosphamide, methotrexate and fluorouracil (CMF) plus or minus depo-buserelin in premenopausal women with lymph node positive breast cancer","volume":"20","author":"Falkson","year":"2001","journal-title":"Proceedings of American Society of Clincial Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0100|cit100","unstructured":"Falkson CI Jooste R Falkson HC Cyclophosphamide, methotrexate and fluorouracil (CMF) plus or minus depo-buserelin in pre-menopausal women with lymph node positive breast cancer Proceedings of the American Society of Clinical Oncology 2001 7b (abstract 1777)"},{"issue":"12","key":"10.1002\/14651858.CD013538-BIB0101|cit101","first-page":"Abstract 45","article-title":"Randomized study of locoregional radiotherapy and ovarian ablation in premenopausal patients with breast cancer treated with adjuvant chemotherapy","volume":"7","author":"Ragaz","year":"1988","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"142a","key":"10.1002\/14651858.CD013538-BIB0102|cit102","first-page":"Abstract 501","article-title":"Can ovarian ablation improve outcome of stage I-II premenopausal breast cancer patients with estrogen receptor positive tumors treated with adjuvant chemotherapy? Long-term analysis of British Columbia randomized trial","volume":"16","author":"Ragaz","year":"1997","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013538-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/ejso.2002.1280","article-title":"Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomised national multicenter study","volume":"28","author":"S\u00f6reide","year":"2002","journal-title":"European Journal of Surgical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD013538-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013538-BIB0105|cit105","first-page":"2325","article-title":"Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin acetate)","volume":"22","author":"Schmid","year":"2002","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD013538-BIB0106|cit106","unstructured":"Untch M Kahlert S Kosse V LHRH-analogue therapy with leuprorelin-acetate three-month depot offers similar efficacy to conventional adjuvant CMF chemotherapy in receptor positive, node positive breast cancer patients San Antonio Breast Cancer Symposium 2003 abstract 40"},{"key":"10.1002\/14651858.CD013538-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/cncr.32057","article-title":"Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): a randomized, controlled, multicenter trial","volume":"125","author":"Yu","year":"2019","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in pre-menopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study","volume":"20","author":"Jonat","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0959-8049(03)00392-7","article-title":"Survival analyses from the ZEBRA study: goserelin (ZoladexTM) versus CMF in premenopausal women with node-positive breast cancer","volume":"39","author":"Kaufmann","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"24","key":"10.1002\/14651858.CD013538-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1200\/JCO.2003.11.064","article-title":"Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group","volume":"21","author":"Haes","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0111|cit111","unstructured":"NCT02132390 Adjuvant toremifene with or without goserelin in premenopausal women with stage I-IIIA, hormonal receptor positive breast cancer accompanied with or without chemotherapy induced amenorrhoea clinicaltrials.gov\/show\/NCT02132390"},{"key":"10.1002\/14651858.CD013538-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2005.12.013","article-title":"Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study","volume":"42","author":"Baum","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2005.04.5393","article-title":"Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients: the International Breast Cancer Study Group Trial VIII","volume":"25","author":"Bernhard","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013538-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1002\/14651858.CD013538-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2165\/00003495-200565180-00011","article-title":"Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women","volume":"65","author":"Cheer","year":"2005","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD013538-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-016-4024-4","article-title":"Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer","volume":"161","author":"Chlebowski","year":"2017","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD013538-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/bmj.317.7167.1246","article-title":"Ovarian ablation in breast cancer, 1986 to 1998: milestones along hierarchy of evidence from case report to Cochrane review","volume":"317","author":"Clarke","year":"1998","journal-title":"BMJ"},{"issue":"9574","key":"10.1002\/14651858.CD013538-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013538-BIB0120|cit120","unstructured":"Davidson NE O'Neill A Vukov A Osborne CK Martino S White D Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101) Proceedings of the American Society of Clinical Oncology 2003"},{"key":"10.1002\/14651858.CD013538-BIB0121|cit121","first-page":"1189","article-title":"Ovarian oblation in early breast cancer: overview of the randomised trials","volume":"348","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013538-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000485","article-title":"Ovarian ablation for early breast cancer (Cochrane Review)","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013538-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000485","article-title":"Ovarian ablation of early breast cancer","author":"Clarke","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013538-BIB0125|cit125","first-page":"66a","article-title":"Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients","volume":"18","author":"Ejlertsen","year":"1999","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013538-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000181318","article-title":"Pharmacology of the luteinising hormone releasing hormone (LHRH) analog \"Zoladex\"","volume":"32 Suppl 1","author":"Furr","year":"1989","journal-title":"Hormonal Research"},{"key":"10.1002\/14651858.CD013538-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(96)90277-9","article-title":"Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality adjusted survival","volume":"347","author":"Gelber","year":"1996","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013538-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004562.pub4","article-title":"LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women","author":"Goel","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013538-BIB0130|cit130","unstructured":"GRADEproGDT: GRADEpro Guideline Development Tool [software] Hamilton, ON: McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org"},{"issue":"5","key":"10.1002\/14651858.CD013538-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD013538-BIB0132|cit132","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD013538-BIB0133|cit133","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Breast Cancer, version 3.2019, September 6, 2019 NNCN.org (accessed 10 October 2019)"},{"key":"10.1002\/14651858.CD013538-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0959-8049(97)10036-3","article-title":"Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI","volume":"34","author":"Pagani","year":"1998","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013538-BIB0135|cit135","unstructured":"R Foundation for Statistical Computing. Vienna, Austria. ISBN 3-900051-07-0, 2019. Available at http:\/\/www.R-project.org\/ R: a language and environment for statistical computing 2019"},{"issue":"11","key":"10.1002\/14651858.CD013538-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000005.pub4","article-title":"Full publication of results initially presented in abstracts","author":"Scherer","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013538-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glaziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions vesrion 6.0 (updated July 2019). Cochrane, 2019","DOI":"10.1002\/9781119536604.ch15"},{"key":"10.1002\/14651858.CD013538-BIB0138|cit138","first-page":"1293","article-title":"Adjuvant ovarian ablation versus CMF in premenopausal women with pathological stage II breast carcinoma: the Scottish trial","volume":"341","author":"Scottish Cancer Trials Breast Group (SCTBG) and ICRF Breast Unit Guys Hospital London","year":"1993","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013538-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","article-title":"Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer","volume":"24","author":"Walshe","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013538-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000027.pub2","article-title":"Methods for obtaining unpublished data","author":"Young","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013538-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.breast.2005.02.001","article-title":"Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer","volume":"14","author":"Sharma","year":"2005","journal-title":"The Breast"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:13:23Z","timestamp":1695867203000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD013538"}},"subtitle":[],"editor":[{"name":"Cochrane Breast Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":141,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013538","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]}}}